Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LOXO-338
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LOXO-338 is a novel, orally bioavailable small molecule inhibitor of B-cell lymphoma 2 (BCL2), an anti-apoptotic protein that plays a key role in regulating apoptosis and promoting cell survival in many hematologic malignancies. By selectively inhibiting BCL2 over BCL-xL, LOXO-338 aims to induce apoptosis in malignant cells while minimizing the risk of dose-limiting thrombocytopenia associated with BCL-xL inhibition. Preclinical studies demonstrated selective inhibition of BCL2 and favorable tolerability profiles. Clinical trials have shown preliminary efficacy and good safety in patients with advanced blood cancers such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and Waldenström macroglobulinemia (WM). The drug is being developed by Loxo Oncology at Eli Lilly for the treatment of advanced hematologic malignancies[1][3][4][5][6].
- Brand names
- LOXO-338LOXO338LOXO 338
- Other names
- LOXO-338LOXO338LOXO 338LY-3847429LY3847429LY 3847429
02
Targets
MCL1 (Myeloid cell leukemia sequence 1)BCL2L1 (B-cell lymphoma-extra large protein)
Beyond the preview
Go deeper on LOXO-338.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LOXO-338.